Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 24, No 28 (October 1), 2006: pp. 4553-4557
© 2006 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2006.06.7819

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dilts, D. M.
Right arrow Articles by Schilsky, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dilts, D. M.
Right arrow Articles by Schilsky, R. L.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B

David M. Dilts, Alan B. Sandler, Matthew Baker, Steven K. Cheng, Stephen L. George, Kathleen S. Karas, Stephen McGuire, Gourija S. Menon, Jason Reusch, Debbie Sawyer, Maren Scoggins, Amy Wu, Kai Zhou, Richard L. Schilsky

From the Center for Management Research in Healthcare; Management of Technology Program; Owen Graduate School of Management; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN; and Cancer and Leukemia Group B, Chicago, IL

Address reprint requests to David M. Dilts, PhD, Owen Graduate School of Management, 401 21st Ave S, Nashville, TN 37203; e-mail: david.dilts{at}vanderbilt.edu

PURPOSE: National Cancer Institute–sponsored cooperative oncology groups are major sponsors of phase III clinical trials, yet the time and steps required to design and activate such studies has not been well studied. We examine the processes and document the calendar time required to activate such studies opened by the Cancer and Leukemia Group B (CALGB).

METHODS: Setup steps were documented by (1) interviewing CALGB headquarters and statistical center staff and committee chairs to discover the steps required to transit from concept development to final study activation, (2) reviewing procedure manuals, and (3) inspecting all study records, documents, and e-mails to identify any additional steps. Calendar time was collected for each major process.

RESULTS: Thirteen phase III studies were activated by CALGB during the study period of May 2002 to May 2005. More than 370 distinct processes were required for study activation: 317 work steps, 42 decision points, and 29 processing loops. Sixty-three percent of the decision points were outside CALGB. The complete process map measures 243.5" x 41" in 8-point font. Median calendar days to activate a phase III study at CALGB was 580 days (range, 295 to 1,248 days) from concept approval and 784 days (range, 537 to 1,130 days) from initial conception of the study.

CONCLUSION: Setup of a phase III study at a major cooperative oncology group is a complex and lengthy process, with the majority of decision points external to the cooperative group. To improve the activation process, research should to be directed toward both internal and external groups and processes.

Supported by Grant No. CA 31946 from the National Cancer Institute to R.L.S. and by subcontract to D.M.D. and A.B.S.

Presented in part at the 42nd Annual Meeting of the American Society of Clinical Oncology, June 2-6, 2006, Atlanta, GA.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Elephant Is Monstrous
    David P. Steensma
    JCO 2007 25: 1148 [Full Text]


This article has been cited by other articles:


Home page
JCOHome page
R. Kurzrock, S. Pilat, M. Bartolazzi, D. Sanders, J. Van Wart Hood, S. D. Tucker, K. Webster, M. A. Mallamaci, S. Strand, E. Babcock, et al.
Project Zero Delay: A Process for Accelerating the Activation of Cancer Clinical Trials
J. Clin. Oncol., September 10, 2009; 27(26): 4433 - 4440.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
T. A. McJoynt, M. A. Hirzallah, D. V. Satele, J. H. Pitzen, S. R. Alberts, and S. V. Rajkumar
Building a Protocol Expressway: The Case of Mayo Clinic Cancer Center
J. Clin. Oncol., August 10, 2009; 27(23): 3855 - 3860.
[Abstract] [Full Text] [PDF]


Home page
ANN INTERN MEDHome page
B. R. Luce, J. M. Kramer, S. N. Goodman, J. T. Connor, S. Tunis, D. Whicher, and J. S. Schwartz
Rethinking Randomized Clinical Trials for Comparative Effectiveness Research: The Need for Transformational Change
Ann Intern Med, August 4, 2009; 151(3): 206 - 209.
[Full Text] [PDF]


Home page
JCOHome page
D. M. Dilts, A. B. Sandler, S. K. Cheng, J. S. Crites, L. B. Ferranti, A. Y. Wu, S. Finnigan, S. Friedman, M. Mooney, and J. Abrams
Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program
J. Clin. Oncol., April 10, 2009; 27(11): 1761 - 1766.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. P. Steensma
The Ordinary Miracle of Cancer Clinical Trials
J. Clin. Oncol., April 10, 2009; 27(11): 1737 - 1739.
[Full Text] [PDF]


Home page
NEJMHome page
S. W. Glickman, J. G. McHutchison, E. D. Peterson, C. B. Cairns, R. A. Harrington, R. M. Califf, and K. A. Schulman
Ethical and Scientific Implications of the Globalization of Clinical Research
N. Engl. J. Med., February 19, 2009; 360(8): 816 - 823.
[Full Text] [PDF]


Home page
Arch Intern MedHome page
W. P. Peters
Cooperative Groups Are Not...
Arch Intern Med, October 27, 2008; 168(19): 2172 - 2173.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. M. Dilts, A. Sandler, S. Cheng, J. Crites, L. Ferranti, A. Wu, R. Gray, J. MacDonald, D. Marinucci, and R. Comis
Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group
Clin. Cancer Res., June 1, 2008; 14(11): 3427 - 3433.
[Abstract] [Full Text] [PDF]


Home page
J Oncol PractHome page
L. R. Bressler and R. L. Schilsky
Collaboration Between Cooperative Groups and Industry
J. Oncol. Pract, May 1, 2008; 4(3): 140 - 141.
[Full Text] [PDF]


Home page
JCOHome page
A. B. Benson III
From Silos to a Critical Path of New Agent Development: A Paradigm to Revolutionize Clinical Research
J. Clin. Oncol., April 20, 2008; 26(12): 1924 - 1925.
[Full Text] [PDF]


Home page
JCOHome page
D. M. Dilts and A. B. Sandler
In Reply
J. Clin. Oncol., April 20, 2007; 25(12): 1634 - 1634.
[Full Text] [PDF]


Home page
JCOHome page
D. Dilts and A. Sandler
In Reply
J. Clin. Oncol., March 20, 2007; 25(9): 1148 - 1149.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online